Tigo Energy Solar Rapid Shutdown Selected by Constructora San Jose for 142MWp Solar System
6.6.2024 16:00:00 EEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced that premier Engineering, Procurement, and Construction (EPC) firm, Constructora San Jose, S.A., has selected Tigo as the rapid shutdown technology provider for a 142MWp solar installation for an industrial ground mount in Spain. Reliable rapid shutdown functionality is essential to providing fire safety for system owners and eliminates the risk of encountering high-voltage DC electricity for operations and maintenance, as well as emergency personnel in case of contact with the system during service intervals or in emergency situations.
The system, which will produce clean energy to help serve the demand from local industry and feed excess energy back to the public grid, will include more than 107,000 Tigo TS4-A-2F MLPE devices and produce in excess of 142MWp. The project also includes more than 550 Tigo RSS Transmitters with Pure Signal technology, which eliminates disturbances in PLC signals from adjacent cable runs and improves the effectiveness of system communications functions in large and complex systems.
“With the responsibility that comes with a system of this size, the reliability and quality of Tigo was the ideal option for rapid shutdown safety,” said Diego Navarro, purchasing manager at Constructora San Jose, S.A. “In contrast to roof-mounted solar systems, the risk of contact with a ground-mounted system is somewhat higher, which is why reliable rapid shutdown is essential. With a project that will become part of the critical energy infrastructure in the region, it is important to get everything right, and the Tigo Green Glove program has provided outstanding support service throughout the process.”
The TS4-A-2F is a reliable and cost-effective two-module rapid shutdown solution that meets the latest module-level shutdown requirements, including NEC 2017/2020. The TS4-A-2F is both IEC and UL-certified for global acceptance and UL-PVRSS-certified for connectivity with the largest network of inverters. Constructora San Jose selected the TS4-A-2F to support the 670W modules used in the project, which will be under construction during the second half of 2024, with commissioning expected in the first half of 2025.
“It is an honor to have won the trust of Constructora San Jose, S.A. for this project, and we look forward to delivering on Total Quality Solar as the project moves through installation and into the operations phase,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy Inc. “We design our technology to be both reliable and offer design flexibility, and this system once again shows that as system complexity and size increases, Tigo provides a great solution. The Tigo Green Glove support team will be there for the Constructora San Jose team throughout the project, with a focus on end-to-end installation quality and long-term system safety.”
The Tigo TS4 platform maximizes the benefit of PV systems for installers on all continents. With a system size range from 2kW to more than 100MW and installation in less than ten seconds per module, Tigo has a trusted and reliable product portfolio deployed around the world, from rapid shutdown to module-level monitoring and advanced energy optimization.
For more information about the Tigo TS4-A-2F MLPE device, please visit the product website here. For more information about the Tigo Green Glove program for C&I solar installers, please visit the program website here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606641822/en/
Contact information
Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release
Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom